4D Molecular Therapeutics (FDMT) Net Income towards Common Stockholders (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported Net Income towards Common Stockholders of -$68.8 million for Q1 2026, down 43.33% year-over-year from -$121.3 million in Q1 2025, and down 454.49% quarter-over-quarter from $19.4 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$68.8 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$68.8 million, down 43.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$160.9 million (up 8.81% YoY), and the FY2025 annual result was -$140.1 million, up 12.9% from the prior year.
- Net Income towards Common Stockholders retreated to -$68.8 million in Q1 2026 per FDMT's latest filing, from $19.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $19.4 million in Q4 2025 and troughed at -$68.8 million in Q1 2026.
- A 5-year average of -$34.0 million and a median of -$32.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders tumbled 327.49% in 2024, then soared 139.05% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$27.4 million in 2022, then retreated by 17.91% to -$32.3 million in 2023, then tumbled by 53.86% to -$49.7 million in 2024, then surged by 139.05% to $19.4 million in 2025, then tumbled by 454.49% to -$68.8 million in 2026.
- Business Quant data shows FDMT's Net Income towards Common Stockholders at -$68.8 million in Q1 2026, $19.4 million in Q4 2025, and -$56.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -68.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68.76 Mn |
| Dec 31, 2025 | 19.40 Mn |
| Sep 30, 2025 | -56.88 Mn |
| Jun 30, 2025 | -54.66 Mn |
| Mar 31, 2025 | -47.97 Mn |
| Dec 31, 2024 | -49.67 Mn |
| Sep 30, 2024 | -43.84 Mn |
| Jun 30, 2024 | -34.95 Mn |
| Mar 31, 2024 | -32.40 Mn |
| Dec 31, 2023 | -32.28 Mn |
| Sep 30, 2023 | -10.26 Mn |
| Jun 30, 2023 | -29.62 Mn |
| Mar 31, 2023 | -28.68 Mn |
| Dec 31, 2022 | -27.38 Mn |
| Sep 30, 2022 | -25.69 Mn |
| Jun 30, 2022 | -28.09 Mn |
| Mar 31, 2022 | -26.34 Mn |
| Dec 31, 2021 | -25.08 Mn |
| Sep 30, 2021 | -22.24 Mn |
| Jun 30, 2021 | -7.59 Mn |